Recommended for general use within NHS Scotland for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
In clinical trials, tiotropium demonstrated superior efficacy to ipratropium and salmeterol in improving lung function (FEV1). Generally, it has greater efficacy than ipratropium, and similar efficacy to salmeterol in improving dyspnoea, the use of rescue medication, the frequency of COPD exacerbations and hospitalisation due to exacerbations.
Download detailed advice18KB (PDF)
- Medicine name:
- Tiotropium bromide (Spiriva®)
- SMC ID:
- Chronic obstructive pulmonary disease
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Respiratory system
- Submission type
- Date advice published
- 06 December 2002